What are the recommended oral and intravenous dosing regimens for propranolol in adults, including dose titration, maximum doses, and adjustments for hepatic impairment, elderly patients, and contraindications?

Propranolol Dosing

For acute cardiovascular indications in adults, intravenous propranolol should be administered as 0.5-1.0 mg over 1 minute, repeated up to a total dose of 0.1 mg/kg if required, while for oral therapy in acute coronary syndromes, start with 40-80 mg every 6-8 hours after an initial IV load, targeting a resting heart rate of 50-60 beats per minute. 1, 2

Intravenous Dosing

Acute Tachyarrhythmias

• Initial dose: 0.5-1 mg IV over 1 minute
• Repeat dosing: Can repeat up to total dose of 0.1 mg/kg if needed
• Indications: Stable narrow-complex tachycardias, atrial fibrillation/flutter rate control, certain polymorphic VT 1
• Monitoring: Continuous ECG, frequent heart rate and blood pressure checks, auscultation for rales and bronchospasm 2

Acute Coronary Syndromes

• Initial IV dose: 0.5-1.0 mg, followed in 1-2 hours by oral therapy
• Transition to oral: 40-80 mg PO every 6-8 hours after tolerating IV dose 2

Critical contraindications for IV propranolol: Avoid in patients with asthma, decompensated heart failure, bradycardia (<50 bpm), hypotension (SBP <90 mmHg), second- or third-degree heart block, or evidence of low-output state 1, 2, 1

Oral Dosing by Indication

Hypertension and General Cardiovascular Use

• Starting dose: 40 mg twice daily
• Titration: Increase every 2-3 days as tolerated
• Maintenance: 100-200 mg total daily dose
• Maximum: 320 mg/day in patients without ascites; 160 mg/day in patients with ascites 3, 4
• Target: Resting heart rate 55-60 bpm without systolic BP dropping below 90 mmHg 3

Portal Hypertension/Variceal Bleeding Prevention

• Starting dose: 20-40 mg orally twice daily
• Titration: Adjust every 2-3 days
• Maintenance: Target dose to achieve resting heart rate 55-60 bpm
• Maximum: 320 mg/day in patients without ascites; 160 mg/day in patients with ascites 3
• Alternative: Long-acting propranolol 80-160 mg once daily can be used for compliance 4

Important: In severe liver disease (albumin <30 g/L), start with 20 mg three times daily of conventional formulation or 80 mg daily of slow-release preparation, with hospital initiation and close heart rate monitoring 5

Infantile Hemangiomas (Pediatric)

• Starting dose: 1 mg/kg/day divided into 2-3 doses
• Titration: Increase over 2 weeks
• Maintenance: 2-3 mg/kg/day (FDA-approved formulation: 1.7 mg/kg twice daily = 3.4 mg/kg/day) 6, 7
• Duration: Typically 6 months minimum; optimal cessation at 12-15 months of age to minimize rebound 6
• Administration: Give with or after feeding; hold doses during diminished oral intake or vomiting to prevent hypoglycemia 6

For PHACES syndrome or segmental facial hemangiomas: Start at 0.5 mg/kg/day and obtain brain MRI/MRA before full-dose escalation; discuss with pediatric neurology if arterial stenosis present 7

Special Population Adjustments

Hepatic Impairment

Propranolol undergoes extensive hepatic metabolism, and cirrhotic patients show 2-3 fold higher plasma concentrations with decreased clearance and prolonged half-life 8, 9, 5

• Severe cirrhosis (albumin <30 g/L):

  • Start with 20 mg three times daily (conventional) or 80 mg daily (long-acting)
  • Initiate in hospital with close monitoring
  • Titrate slowly based on heart rate response 5

• Cirrhosis with ascites:

  • Maximum dose 160 mg/day (vs 320 mg/day without ascites) 3
  • Monitor for antinatriuretic effects that may worsen fluid retention 10

Elderly Patients

Elderly patients demonstrate elevated plasma concentrations, longer elimination half-life (254 vs 152 minutes), and decreased clearance (8 vs 13 mL/kg/min) 8, 11

• Start at low end of dosing range
• Slower titration intervals
• More frequent monitoring of heart rate and blood pressure
• Consider increased bioavailability when dosing 11

Renal Impairment

Chronic renal failure patients show 2-3 fold higher peak concentrations and reduced clearance 8

• Dose adjustment may be needed in severe renal impairment
• Monitor closely for bradycardia and hypotension
• No specific dosing guidelines established; titrate based on clinical response

Key Clinical Pitfalls

1. Abrupt withdrawal: Can precipitate rebound hypertension, angina, or arrhythmias in cardiovascular patients. However, in infantile hemangiomas, abrupt cessation is safe 7

2. Hypoglycemia risk: Particularly in neonates, preterm infants, those with low weight or faltering growth. Always administer with/after feeding and hold during poor oral intake 6, 7

3. Reactive airway disease: While not an absolute contraindication for oral therapy, use beta-1 selective agents (metoprolol, esmolol) preferentially. If propranolol necessary, start with very low doses (12.5 mg) 2

4. Cirrhosis with decompensation: In patients with severe circulatory dysfunction or refractory ascites, propranolol may worsen renal perfusion and should be used cautiously or avoided 12

5. Drug interactions: Propranolol levels significantly increased by CYP2D6 inhibitors (quinidine, fluoxetine, paroxetine), CYP1A2 inhibitors (ciprofloxacin, fluvoxamine), and CYP2C19 inhibitors (fluconazole) 8

6. Non-responders: Approximately 50% of patients with portal hypertension do not achieve adequate HVPG reduction with propranolol; consider switching to carvedilol in these cases 13